Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial

Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Neurol
Hlavní autoři: Dörr, Jan, Wernecke, Klaus-Dieter, Würfel, Jens, Bellmann-Strobl, Judith, Siffrin, Volker, Sättler, Muriel B., Simons, Mikael, Linsa, Andreas, Tumani, Hayrettin, Paul, Friedemann
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2018
Témata:
Neurology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190842/
https://ncbi.nlm.nih.gov/pubmed/30356868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2018.00842
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky